Drugs to Fight Cardiovascular Damage: 2014 EACPT Focus Meeting: July 3-5, 2014 in Nijmegen, the Netherlands

The 2014 EACPT Focus Meeting was on the theme of 'Drugs to Fight Cardiovascular Damage'. This 2014 EACPT Focus Meeting took place from July 3rd - 5th at the Radboud University Medical Center in Nijmegen in the Netherlands.

The 2014 EACPT Focus Meeting

• continued excellent tradition of EACPT in providing outstanding meetings for young and senior clinicians and researchers
• provided delegates with the opportunity to attend state of the art lectures from leading professionals and researchers, including hands-on workshops. 
• provided great opportunities for networking with your peers and senior members of the international clinical pharmacology community
• gave easy access for delegates to senior researchers on the international speaker faculty 
• gave the opportunity to have first hand news on major developments for EACPT
• allowed delegates to meet Dr Richard Shader, the editor of the EACPT's Official Journal - Clinical Therapeutics 
• provided delegates with an expert session from Dr Shader on how to publish

In addition to state-of-the-art lectures from international cardiovascular experts, over 60 delegate abstracts were presented  from around the world, with the top 5 ranked abstract presenters  provided with free registration. All abstracts presented at the meeting were published in Clinical Therapeutics, the peer-reviewed Official Journal of the EACPT. 

Selected publications based on the lectures at the Focus Meeting will be published in Clinical Therapeutics. 

This focus meeting follows on from the highly rated  EACPT international summer school in 2013 in Edinburgh.

Radboud University Medical Centre, Nijmegen 

Topics included ultrasound imaging of vascular injury (including a hands-on workshop), the microbiome and inflammation in the metabolic syndrome, targeting inflammation to prevent and treat atherosclerosis, diagnosis and therapy of adrenal hypertension, and protection against ischaemia-reperfusion injury.

This EACPT Cardiovascular Focus Meeting was attended by clinical pharmacologists, pharmacologists, and other young scientists and clinicians interested in drug treatment of cardiovascular disease. 

You can listen here to podcasts with international delegates at the last EACPT summer meeting in Edinburgh in 2013.


Visit the Clinical Therapeutics website.

Register for final places for excellent EACPT summer cardiovascular focus meeting 3-5 July in Holland

You are still in time to register for 2014 EACPT Focus Meeting on 'Drugs to Fight Cardiovascular Damage' from organised by the the European Association for Clinical Pharmacology and Therapeutics [EACPT] .

Registration  - with a preferential accommodation rate - is available through the Focus Meeting website.

The 2014 EACPT Focus Meeting takes place from July 3rd - 5th at the Radboud University Medical Center in Nijmegen in the Netherlands.

Reasons to come to this outstanding meeting

• excellent tradition of EACPT in providing outstanding meetings for young and senior clinicians and researchers
• great opportunities for networking with your peers and senior members of the international clinical pharmacology community
• easy access to senior researchers on the international speaker faculty 
• opportunity to have first hand news on major developments for EACPT
• meet Dr Richard Shader, the editor of the EACPT's Official Journal - Clinical Therapeutics 
• expert session from Dr Shader on how to publish

In addition to state-of-the-art lectures from international cardiovascular experts, over 60 delegate abstracts are due be presented  from around the world. The top 5 ranked abstracts will be provided with free registration. All abstracts presented at the meeting will be published in Clinical Therapeutics, the peer-reviewed Official Journal of the EACPT. 

This focus meeting follows on from the highly rated  EACPT international summer school in 2013 in Edinburgh.

The 2014 EACPT Focus Meeting will provide you with the opportunity to attend state of the art lectures from leading professionals and researchers, including hands-on workshops. 

Radboud University Medical Centre, Nijmegen 

Topics include ultrasound imaging of vascular injury (including a hands-on workshop), the microbiome and inflammation in the metabolic syndrome, targeting inflammation to prevent and treat atherosclerosis, diagnosis and therapy of adrenal hypertension, and protection against ischaemia-reperfusion injury.

This EACPT Cardiovascular Focus Meeting is of interest to clinical pharmacologists, pharmacologists, and other young scientists and clinicians interested in drug treatment of cardiovascular disease. 

You can listen here to podcasts with international delegates at the last EACPT summer meeting in Edinburgh in 2013.

See the Scientific Programme is now online on the Focus Meeting website. 

Visit the Clinical Therapeutics website.

Update on July 3-5 EACPT Cardiovascular Focus Meeting in the Netherlands

Following the well-attended EACPT international summer school in 2013 in Edinburgh, the next European Association for Clinical Pharmacology and Therapeutics [EACPT] update for young researchers is the 2014 EACPT Focus Meeting on 'Drugs to Fight Cardiovascular Damage'. The EACPT Focus Meeting will provide you with the opportunity to attend state of the art lectures from leading professionals and researchers, including hands-on workshops. 
Topics include ultrasound imaging of vascular injury (including a hands-on workshop), the microbiome and inflammation in the metabolic syndrome, targeting inflammation to prevent and treat atherosclerosis, diagnosis and therapy of adrenal hypertension, and protection against ischaemia-reperfusion injury.

This EACPT Cardiovascular Focus Meeting is of interest to clinical pharmacologists, pharmacologists, and other young scientists and clinicians interested in drug treatment of cardiovascular disease. You can listen here to podcasts with international delegates at the last EACPT summer meeting in Edinburgh in 2013.

The abstract deadline is April 15th - the top 5 ranked abstracts will be provided with free registration. Abstract submission is online on the Focus Meeting website. There are opportunities for both oral and poster presentations within the overall scientific program.  All abstracts presented at the meeting will be published in Clinical Therapeutics, the peer-reviewed Official Journal of the EACPT. 

Registration is now open - with preferential rates if you register by May 15th. A preferential accommodation rate is available through the Focus Meeting website.

The Scientific Programme is now online on the Focus Meeting website. The 2014 EACPT Focus Meeting takes place from July 3rd - 5th at the Radboud University Medical 

Radboud University Medical Centre, Nijmegen

Center in Nijmegen in the Netherlands. 
Visit the Clinical Therapeutics website.

Register interest in the EACPT

The EACPT is planning to launch Individual EACPT Associates as a new opportunity to become part of the EACPT and to support its activities. Benefits for Individual EACPT Associates will include

• online access to our official journal – Clinical Therapeutics
• 50% reduction in page charges for publishing in the journal
• involvement in EACPT working groups and other EACPT activities
• opportunities to become involved in partner activities between the EACPT and other organisations

The Individual EACPT Associates initiative will be launched in the Spring of 2014.

2014 EACPT Focus Meeting: 'Drugs to Fight Cardiovascular Damage' 3-5 July, 2014

Following the well-attended EACPT international summer school in 2013 in Edinburgh, the next European Association for Clinical Pharmacology and Therapeutics [EACPT] update for young researchers is the 2014 EACPT Focus Meeting on  'Drugs to Fight Cardiovascular Damage'.

The 2014 EACPT Focus Meeting takes place from July 3rd - 5th at the Radboud University Medical

Radboud University Medical Centre, Nijmegen

Center in Nijmegen in the Netherlands. 

This EACPT cardiovascular focus meeting is of interest to clinical pharmacologists, pharmacologists, and other young scientists and clinicians interested in drug treatment of cardiovascular disease. 

Topics include: 
- ultrasound imaging of vascular injury (including a workshop tproviding t hands-on training),
- the microbiome and inflammation in the metabolic syndrome
- targeting inflammation to prevent and treat atherosclerosis
- diagnosis and therapy of adrenal hypertension
- protection against ischaemia-reperfusion injury. 

Provisional State of the Art Lectures by invited speakers include:

Arterial stiffness measurements; methods and relevance for risk assessment and drug-research: Stephane Laurent, Paris, France

IMT measurement with ultrasound, methods and relevance for risk assessment and drug research: Luc van Bortel, Gent, Belgium

The microbiome in the pathogenesis of metabolic syndrome: Max Nieuwdorp

Fat cells and inflammation in the pathogenesis of the Metabolic Syndrome: Rinke Stienstra, Nijmegen, The Netherlands

Predicting and manipulating drug inactivation by the human gut microbiome: H. Haiser. FAS Center for Systems Biology, Harvard University, USA

Cardiac protection by conditioning: from bench to bedside: D. Hausenloy, Hatter Institute, London

The role of hexokinase in cardioprotection: C. Zuurbier, Amsterdam, The Netherlands

Wnt pathways in cardiac repair and remodeling: M. Blankesteijn

Targeting the adaptive immune system in atherosclerosis: Esther Lutgens, AMC, Amsterdam

Trained immunity in the pathogenesis of atherosclerosis: Niels Riksen, Nijmegen, The Netherlands

The pathogenesis of autonomous adrenal aldosterone release: Felix Beuschlein

Diagnosis and treatment of hyperaldosteronism: Jaap Deinum, Nijmegen, The Netherlands

Health professional scientists, academics and  professionals from the pharmaceutical, biotechnology, and related sectors are invited to submit their latest scientific results for oral or poster presentation.

For more information, email  eacpt2014@kenes.com.

Abstract submission and registration will open shortly on our dedicated website.

Abstracts will be published online in Clinical Therapeutics, the Official Journal of the EACPT.

Update from London on the EACPT

The Executive Committee of the European Association for Clinical Pharmacology and Therapeutics (EACPT) met in London 12-13 October, hosted by the British
Pharmacological Society. The main business of this EC meeting was planning for major pending events and activities. Key items included:

Members of the EACPT Executive Committee

the 12th biennial EACPT congress to be held from 27-29 June 2015 in Madrid 
- the EACPT focus meeting in Nijmegen in the Netherlands, 3-5 July 2014 - the key theme is cardiovascular.
- update on the official EACPT journal Clinical Therapeutics (online access is a benefit for individual Associates of the EACPT - see register interest link below) 
- interaction with key policy organisations interested in medicines and patient safety, including the European Medicines Agency. EACPT chair Professor Gonzalo Calvo is inaugural co-chair of the Healthcare Professionals Working Party of the 

European Medicines Agency. 

The above photo, taking at the British Pharmacological Society offices, shows: 

Back row: Dinko Vitezić (Croatia), Simon Maxwell (UK), Donald Singer (UK), Ingolf Cascorbi (Germany), Ádám Vas (Hungary), Gerard Rongen (Netherlands) 

Front row: Gonzalo Calvo (Spain), Caridad Pontes (Spain), Marie Besson (Geneva), Ylva Böttiger (Sweden),  Caroline Samer (Geneva). 

Also at the meeting were Professor Kim Brosen (Denmark) and EACPT Chair-elect Professor Tabassome Simon (France).

Parliament buildings and former County Hall

EACPT biennial congresses provide excellent opportunities to showcase issues of topical international concern to the CPT community, through timely and accessible original research presentations and commentaries to policy-makers, health and industry professionals, health technology providers, patient groups and academia. 

The Madrid 2015 Congress will bring together a wide range of international delegates, including health professionals, clinical and life scientists, policy makers, professionals from the biotechnology and pharmaceutical communities and others interested in the spectrum from basic to clinical pharmacology and pharmacotherapy, and from drug discovery to regulatory affairs. 

Co-organisers Marie Besson and Caroline Samer reported on the recent Geneva EACPT Congress. Almost 600 delegates attended the 11th EACPT Congress in Geneva in August 2013, where there were 101 invited speakers from 21 countries - 15 countries from the European region and a further 6 countries internationally, from the USA, Canada, New Zealand, China, Benin and India. 330 abstracts were presented as oral and poster communications, following submissions from 57 countries from all 5 continents.

EACPT EC members Caridad Pontes (Spain), Adam Vaz (Hungary), Marie Besson (Switzerland) and Gonzalo Calvo (EACPT Chair: Spain) are members of the organizing committee for the 2015 EACPT Congress in Madrid. 

Key themes at the Madrid congress will include translational medicine and pharmacogenetics, advances in personalised diagnostics to improve the safety and effectiveness of medicines, updates on new biological approaches to disease, therapeutics of cardiovascular, cancer and inflammatory disease, clinical trial design and regulation, drug safety and toxicology, clinical trial design and governance, health policy and safe prescribing.

Register below interest in becoming an individual Associate of the EACPT and in future EACPT activities. 

Transcript of podcast by Tabassome Simon on Clinical Pharmacology and FAST-MI

Listen to podcast of Professor Tabassome Simon discussing Clinical Pharmacology and the FAST-MI Registry.

DS     I am in Geneva at the 11^th EACPT Congress with Professor Tabassome Simon.  

FAST-MI co-author Ziad Mallat with EACPT Chair-Elect Tabassome Simon & EACPT Secretary Donald Singer

Tabassome, would you comment on the ways in which your expertise as a Clinical Pharmacologist has contributed to the success of the Fast-MI Registry.

TS      Since I am a Clinical Pharmacologist, I would just focus on papers emerged from my interests as a clinical pharmacologist.

What is great about being all together in different fields, is talking together.  We have different visions of the same issue and that gives us really strength, our way of looking at disease and that is what clinical pharmacology is about. 

One example of which we are very proud was the paper that we did that was published in the New England Journal of Medicine regarding the impact of polymorphisms for metabolism and transporters ABCB1 and CYP2C19 onoutcomes for those who were receiving clopidogrel. 

That was the first paper that we did together, with another team from the United States who did a trial called Triton with prasugrel and clopidogrel.  Both papers were published in the New England Journal of Medicine and that was a huge hit in 2009.  Later on, several other papers were focussed on this genotyping process, including with the Plato trial with ticagrelor.

One further aspect that FAST-MI brought us [was recording] concomitant drugs which were usually not taken into account in registries, in particular for PPIs -  proton pump inhibitors. We had that [information] and so we could look also at the impact of drug interactions. We published that in Circulation.

Later on we did several papers with Ziad Mallat and other colleagues regarding the impact of lipases such as sPLA2, both [from studies] in blood but also [from studies of] Mendelian randomisation. The paper is in press actually, in the Journal of American College of Cardiology, and will be published soon. Another paper regarding BAFF targeting B cells will be published in Nature Medicine this year.

DS     Tabassome Simon, thank you very much.

Selected references from FAST-MI publications

Simon T., Verstuyft C., Mary-Krause M, Quteineh L., Drouet E., Meneveau N., Steg P.G., Ferrieres J., Danchin N., Becquemont L., for the French Registry of Acute ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009;360 : 363-75

Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, Khalife K, Goldstein P, Cattan S, Vaur L, Cambou JP, Ferrières J, Danchin N; USIK USIC 2000 Investigators; FAST MI Investigators. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998-1006.

Simon T, Steg Ph G, Gilard M, Blanchard D,  Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre Th, Drouet E , Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N. Clinical events as a function of PPI use, clopidogrel use and CYP2C19 genotype in a large nationwide cohort of acute myocardial infarction: Results from the FAST-MI Registry; Circulation 2011, 123:474-482

Danchin N, Coste P, Ferrieres J, STEG G, Cottin Y, Blanchard D, Belle L, Ritz B, Kirkorian G, Angioi M, Sans Ph, Charbonnier B, Eltchaninoff H, Gueret P, Khalife K, Asseman Ph , Puel J, Cambou J-P, Simon T. A comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary PCI for ST segment elevation acute myocardial infarction. Circulation 2008; 118: 268-276

Lind L.†, Simon T. †, Johansson L., Kotti S., Hansen T.,Machecourt J., Ninio E., Tedgui A., Danchin N.,Hakan Ahlstrom, Mallat Z. Circulating levels of secretory- and lipoproteinassociated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J, 2012; 33:2946-54. †contributed equally to this work

Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-30.

Aissaoui N, Puymirat E, Tabone X, Charbonnier B, Schiele F, Lefèvre T, Durand E, Blanchard D, Simon T, Cambou JP, Danchin N.Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries. Eur Heart J. 2012;33(20):2535-43.

Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, Montely JM, Dubourg O, Tedgui A, Kotti S, Mallat Z.Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570-7

Simon T, Steg PG, Becquemont L, Verstuyft C, Kotti S, Schiele F, Ferrari E, Drouet E, Grollier G, Danchin N. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther. 2011;90(4):561-7

Lim P, Moutereau S, Simon T, Gallet R, Probst V, Ferrieres J, Gueret P, Danchin N. Usefulness of Fetuin-A and C-Reactive Protein Concentrations for Prediction of Outcome in Acute Coronary Syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction. Am J Cardiol.2013;111:31-7

Hanssen M, Cottin Y, Khalife K, Hammer L, Goldstein P, Puymirat E, Mulak G, Drouet E, Pace B, Schultz E, Bataille V, Ferrières J, Simon T, Danchin N.  French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. Heart. 2012;98:699-705.

Puymirat E, Taldir G Aissaoui  N, Lemesle G., Lorgis L., Cuisset Th., Bourlard P., Maillier B., Ducrocq G. , Ferrieres J, Simon T, Danchin N. Use of Invasive Strategy In Non-ST-Elevation Myocardial Infarction Is a Major Determinant of Improved Long-Term Survival. The FAST-MI Registry. JACC Cardiovasc Interv 2012;5(9):893-902.

Belle L, Labarère J, Fourny M, Drouet E, Mulak G, Dujardin JJ, Vilarem D, Bonnet P, Hanssen M, Simon T, Ferrières J, Danchin N; French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction study investigators. Quality of care for myocardial infarction at academic and nonacademic hospitals. Am J Med. 2012;125(4):365-73.

Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P, Wyart P, Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G, Bataille V, Cambou JP, Ferrieres J, Simon T; for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators. Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular Outcomes in Diabetic Patients with Acute Myocardial Infarction.  J Clin Endocrinol Metab. 2010;95:4993-5002

Danchin N,  Fauchier L, Marijon E, Barnay C, Furber A, Mabo Ph, Bernard P, Blanc JJ, Jouven X, Le Heuzey JY, Charbonnier B,  Ferrieres J,  Simon T . Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. Heart 2010;96:1809-1814

Puymirat E, Aïssaoui N, Collet JP, Chaib A, Bonnet JL, Bataille V, Drouet E, Mulak G, Ferrières J, Blanchard D, Simon T, Danchin N. Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry. Int J Cardiol, 2011, Nov 10. [Epub ahead of print]

Puymirat E, Aïssaoui N, Coste P, Dentan G, Bataille V, Drouet E, Mulak G, Carrié D, Blanchard D, Simon T, Danchin N. Comparison of Efficacy and Safety of a Standard Versus a Loading Dose of Clopidogrel for Acute Myocardial Infarction in Patients ≥75 Years of Age from the FAST-MI Registry. Am J Cardiol. 2011;108:755-9

Simon T, Mary-Krause M, Cambou JP, Hanania G., Guéret P., Lablanche JM, Blanchard D, Genès N, Vaur L, Danchin N on behalf of the USIC investigators. Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: increased early risk in younger women. Results from the French nation-wide USIC registries. Eur Heart J, 2006, 27 (11) : 1282-8.

Patrick Mismetti on clinical drug development of new anticoagulants

At the 11th EACPT Congress in Geneva, Professor Patrick Mismetti from St Etienne in France, in a podcast with EACPT Secretary Donald Singer discusses
- training in Clinical Pharmacology
- the contribution of Clinical Pharmacology to research on anticoagulants
- advantages and challenges to the use of new anticoagulant
Listen to the podcast with Patrick Mismetti on clinical drug development of new anticoagulants

Around 600 young and senior pharmacologists and other delegates from 5 continents were in Geneva at the end of August, for the 11th biennial Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT).

More about the 11th EACPT Congress in Geneva.

Paddle steamer by Hôtel de la Paix, Geneva

View and download Congress Programme

View Congress Abstracts ONLINE at the Clinical Therapeutics website.

The Geneva Congress brought together a wide range of international delegates, including health professionals, clinical and life scientists, policy makers, professionals from the biotechnology and pharmaceutical communities and others interested in the spectrum from basic to clinical pharmacology and pharmacotherapy, and from drug discovery to regulatory affairs. For the Geneva Congress, there were 101 invited speakers from 21 countries - 15 from the European region and a further 6 countries internationally, from the USA, Canada, New Zealand, China, Benin and India. Around 300 abstracts from 57 countries from all 5 continents were presented as oral and poster communications.

Future EACPT Congresses and Summer Schools
2014 - 11th EACPT Summer School - Nijmegen: 5-8 July
2015 - 12th EACPT Congress - Madrid
2017 - 13th EACPT Congress - Prague
2019 - 14th EACPT Congress - Stockholm   

EACPT website

Tabassome Simon discusses Clinical Pharmacology and the FAST-MI Registry

At the 11th EACPT Congress in Geneva, EACPT Vice-Chairman Professor Tabassome Simon from Paris discussed results on inflammatory mediators and outcomes of acute coronary syndromes, based on data from the French FAST-MI Registry.
In a podcast discussion with EACPT Secretary Donald Singer, Tabassome Simon discusses- the origins and significance of the FAST-MI French Registry of patients with acute coronary syndromes
- the contribution of Clinical Pharmacology to the success of FAST-MI 
- the strengths of including non-cardiological drugs in FAST-MI
- the strengths of bio-banking serological and genetic samples in FAST-MI

1. Listen to the podcast with Tabassome Simon about the origins and importance of the FAST-MI Registry.

2. Listen to Tabassome Simon discussing the role of Clinical Pharmacology in FAST-MI Registry.  Download transcript

FAST-MI collaborator Ziad Mallat with EACPT Vice-Chair Tabassome Simon and EACPT Secretary Donald Singer

Weblinks for selected FAST-MI publications


Around 600 young and senior pharmacologists and other delegates from 5 continents were in Geneva at the end of August, for the 11th biennial Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). 

More about the 11th EACPT Congress in Geneva.

Paddle steamer by Hôtel de la Paix, Geneva

View and download Congress Programme

View Congress Abstracts ONLINE at the Clinical Therapeutics website.

The Geneva Congress brought together a wide range of international delegates, including health professionals, clinical and life scientists, policy makers, professionals from the biotechnology and pharmaceutical communities and others interested in the spectrum from basic to clinical pharmacology and pharmacotherapy, and from drug discovery to regulatory affairs. For the Geneva Congress, there were 101 invited speakers from 21 countries - 15 from the European region and a further 6 countries internationally, from the USA, Canada, New Zealand, China, Benin and India. Around 300 abstracts from 57 countries from all 5 continents were presented as oral and poster communications.

Future EACPT Congresses and Summer Schools
2014 - 11th EACPT Summer School - Nijmegen: 5-8 July
2015 - 12th EACPT Congress - Madrid
2017 - 13th EACPT Congress - Prague
2019 - 14th EACPT Congress - Stockholm  

EACPT Lifetime Achievement Awards presented in Geneva to Professor Sir Michael Rawlins and Professor Carlo Patrono

Today in Geneva, EACPT Lifetime Achievement Awards were presented to Professor Carlo Patrono and to Professor Sir Michael Rawlins for their outstanding contributions to the national and international benefits of clinical pharmacology for medicine, health care and patient safety.

Sir Michael Rawlins and Carlo Patrono

These Awards, including the EACPT silver medal, were presented at an Awards Ceremony the 11th EACPT Congress in Geneva, 28th - 31st August 2013 by EACPT co-founder Professor Folke Sjöqvist, and by Dr Marie Besson, co-leader of the 2011 EACPT Congress.

Carlo Patrono is Professor and Chair of the Department of Pharmacology at the Catholic University School of Medicine (UCSC) in Rome, Italy.  He is also the Chairman of the Task Force on Antiplatelet Agents of the European Society of Cardiology.

Prof. Patrono’s main research interest is in the study of platelet activation and inhibition in atherothrombosis. He pioneered development of radioimmunoassays for measuring prostanoid and isoprostane biosynthesis in health and disease. His research has characterized the human pharmacology of aspirin as an inhibitor of platelet COX-1 and provided the basis for the development of low-dose aspirin as an antithrombotic agent. During the past decade Prof. Patrono has contributed to characterizing the human pharmacology of COX-2 inhibitors and evaluating their cardiovascular effects in different clinical settings.

For development of low-dose aspirin for the prevention of cardiovascular disease, Professor Patrono was joint recipient with Garret FitzGerald in April 2013 from the Institut de France of the 500,000 euro 2013 Grand Prix Scientifique, the world’s most prestigious prize for cardiovascular research.  

He has also received the Alexander B. Gutman award from the Mount Sinai School of Medicine, the Distinguished Award in Neuroscience from the Louisiana State University, the 1998 International Aspirin® Award from Bayer AG, the 2007 John Vane Award from the William Harvey Research Institute of the University of London, and the 2011 Outstanding Achievement Award of the Eicosanoid Research Foundation. 

Professor Sir Michael Rawlins

Michael Rawlins was from 1999-2013 the first chairman of the National Institute for Health and Clinical Excellence (NICE), and from 1998-2008, Chairman of the Advisory Council on the Misuse of Drugs. He was also Professor of Clinical Pharmacology at the University of Newcastle upon Tyne from 1973 – 2006) and from 1992-1998 Chairman of the UK Committee on the Safety of Medicines, which advised UK government ministers on marketing authorization for new pharmaceuticals, and on withdrawal of medicines in the event of safety concerns. He is currently President of the Royal Society of Medicine and Chairman of the UK Biobank.

As Chairman of NICE, he led one of the world’s most important healthcare organizations, which, based on clinical and cost-effectiveness, guides the National Health Service on whether medicines and other health technologies should be available to patients, and develops evidence-based clinical guidelines for health professionals. Many countries have studied the work of NICE and adopted its ideas and innovations.

Sir Michael’s outstanding scientific contributions have been recognised by the award of numerous honours and distinctions, including his appointment as Knight Bachelor in 1999 for “services to the improvement of patient protection from the side effects of medicinal drugs”. 

Jamie Coleman, Sir Michael Rawlins, Philip Routledge and Donald Singer

The EACPT was founded 20 years ago and now includes all national organisations for clinical pharmacology in Europe. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Official EACPT journal: Clinical Therapeutics 

Future EACPT Congresses and Summer Schools
2014 - 11th EACPT Summer School - Nijmegen: 5-8 July
2015 - 12th EACPT Congress - Madrid
2017 - 13th EACPT Congress - Prague
2019 - 14th EACPT Congress - Stockholm